A Study of ABT-888 in Combination With Carboplatin and Gemcitabine in Subjects With Advanced Solid Tumors

Inclusion Criteria: * Histologically or cytologically confirmed solid tumors that are metastatic or unrespectable for which carboplatin/gemcitabine is a treatment option. * Eastern Cooperative Group performance score of 0 to 2. * Adequate hematologic, hepatic and renal function * Subject has received up to 2 DNA damaging or cytotoxic regimens in the past five years Exclusion Criteria: * Subject has received any anti-cancer therapy including chemotherapy, immunotherapy, radiotherapy, biologic or any investigational therapy within 28 days prior to study administration. * Subjects with known history of brain metastases and primary CNS tumors. * Hypersensitivity reactions to platinum compounds or gemcitabine. * Clinically significant and uncontrolled major medical conditions * Active malignancy within the past 5 years except for any cancer in situ cured or non-melanoma carcinoma of the skin.